BIOLINERX Ltd/S (NASDAQ:BLRX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Wednesday.
According to Zacks, “Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company’s portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. “
Several other research firms have also recently issued reports on BLRX. ValuEngine upgraded BIOLINERX Ltd/S from a “hold” rating to a “buy” rating in a research report on Thursday, October 4th. HC Wainwright set a $4.00 price objective on BIOLINERX Ltd/S and gave the stock a “buy” rating in a research report on Wednesday, October 3rd. Maxim Group reiterated a “buy” rating and issued a $2.00 price objective on shares of BIOLINERX Ltd/S in a research report on Monday, August 13th. Finally, MED began coverage on BIOLINERX Ltd/S in a research report on Wednesday, August 1st. They issued a “market perform” rating for the company. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $2.50.
BIOLINERX Ltd/S (NASDAQ:BLRX) last released its quarterly earnings data on Monday, August 13th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.06) by $0.01. Sell-side analysts anticipate that BIOLINERX Ltd/S will post -0.22 EPS for the current fiscal year.
An institutional investor recently bought a new position in BIOLINERX Ltd/S stock. Fosun International Ltd purchased a new stake in BIOLINERX Ltd/S (NASDAQ:BLRX) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,357,415 shares of the biotechnology company’s stock, valued at approximately $1,412,000. Fosun International Ltd owned approximately 1.27% of BIOLINERX Ltd/S as of its most recent SEC filing. Hedge funds and other institutional investors own 34.69% of the company’s stock.
BIOLINERX Ltd/S Company Profile
BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.
Featured Story: Outstanding Shares, Buying and Selling Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BIOLINERX Ltd/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX Ltd/S and related companies with MarketBeat.com's FREE daily email newsletter.